Literature DB >> 20855037

The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.

Kevin X Chen1, F George Njoroge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20855037     DOI： 10.1016/S0079-6468(10)49001-3

Source DB:  PubMed          Journal:  Prog Med Chem        ISSN： 0079-6468


× No keyword cloud information.
  7 in total

1.  Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.

Authors:  Micaela B Reddy; Peter N Morcos; Sophie Le Pogam; Ying Ou; Karl Frank; Thierry Lave; Patrick Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 2.  Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-12-24       Impact factor: 9.546

3.  Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization.

Authors:  J Brad Shotwell; Subramanian Baskaran; Pek Chong; Katrina L Creech; Renae M Crosby; Hamilton Dickson; Jing Fang; Dulce Garrido; Amanda Mathis; Jack Maung; Derek J Parks; Jeffrey J Pouliot; Daniel J Price; Roopa Rai; John W Seal; Uli Schmitz; Vincent W F Tai; Michael Thomson; Mi Xie; Zhiping Z Xiong; Andrew J Peat
Journal:  ACS Med Chem Lett       Date:  2012-05-24       Impact factor: 4.345

4.  Modular Synthesis of Cyclopropane-Fused N-Heterocycles Enabled by Underexplored Diazo Reagents.

Authors:  Matthieu J R Richter; Frédéric J Zécri; Karin Briner; Stuart L Schreiber
Journal:  Angew Chem Int Ed Engl       Date:  2022-04-25       Impact factor: 16.823

5.  Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).

Authors:  Ahmed A Ezat; Nihal S El-Bialy; Hamdy I A Mostafa; Medhat A Ibrahim
Journal:  Protein J       Date:  2014-02       Impact factor: 2.371

6.  Plasmodium subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target.

Authors:  Chrislaine Withers-Martinez; Catherine Suarez; Simone Fulle; Samir Kher; Maria Penzo; Jean-Paul Ebejer; Kostas Koussis; Fiona Hackett; Aigars Jirgensons; Paul Finn; Michael J Blackman
Journal:  Int J Parasitol       Date:  2012-04-27       Impact factor: 3.981

7.  Inhibition of Hepatitis E Virus Replication by Novel Inhibitor Targeting Methyltransferase.

Authors:  Preeti Hooda; Meenakshi Chaudhary; Mohammad K Parvez; Neha Sinha; Deepak Sehgal
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.